Janus kinase 1/2 inhibition with Baricitinib for treatment of anti-signal recognition particle necrotizing autoimmune myositis: a case report

Main Article Content

Watanyu Phadungvorasart
Kongkiat Kulkantrakorn

Abstract

Following recent success in dermatomyositis treatments, Baricitinib, a selective Janus Kinase 1/2 (JAK1/JAK2) inhibitor, has been the subject of speculation as a potential new remedy for IIM. In this case report, our patient was presented with a typical clinical symptoms of necrotizing autoimmune myositis (NAM), a subset under an umbrella of idiopathic inflammatory myopathy (IIM), and was treated according to European neuromuscular center’s (ENMC) protocol but to no avail. It was then decided that Baricitinib would be administrated as a rescue treatment. In that order, this has become the very first documented use of Baricitinib against the IIM other than dermatomyositis. Despite the unfortunate adverse events of disseminated tuberculosis, Baricitinib has indeed shown a positive outcome for the patient, suggesting a possibility for future developments and treatments of NAM. 

Article Details

How to Cite
1.
Phadungvorasart W, Kulkantrakorn K. Janus kinase 1/2 inhibition with Baricitinib for treatment of anti-signal recognition particle necrotizing autoimmune myositis: a case report. BKK Med J [Internet]. 2023 Sep. 30 [cited 2024 Apr. 25];19(2):121. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/259860
Section
Case Report

References

Albrecht K, Huscher D, Callhoff J, et al. Trends in idiopathic inflammatory myopathies: cross-sectional data from the German National Database. Rheumatol Int 2020;40(10):1639-47. doi: 10.1007/s00296-020-04634-0

Ladislau L, Suárez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 2018;141(6):1609-1621. doi:10.1093/brain/awy105

Papadopoulou C, Hong Y, Omoyinmi E, et al. Janus kinase 1/2 inhibition with Baricitinib in the treatment of juvenile dermatomyositis. Brain 2019;142(3):e8-e8. doi:10.1093/ brain/awz005

Glaubitz S, Zeng R, Schmidt J. New insights into the treatment of myositis. T h e r A d v M u s c u l o s k e l e t D i s 2020;12:1759720X1988649. doi:10.1177/1759720x19886494

Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop: Clinico-sero-pathological classifica tion of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2018;28(1):87-99. doi:10.1016/j.nmd.2017.09.016

Allenbach Y, Benveniste O, Stenzel W, et al. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 2020;16(12):689–701. doi:10.1038/s41584- 020-00515-9

Selvaraj V, Finn A, Lal A, et al. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials. EClinicalMedicine 2022;49:101489. doi: 10.1016/j.eclinm.2022.101489. 8. Winthrop KL, Harigai M, Genovese MC, et al. Infections in Baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis 2020;79(10):1290-7. doi: 10.1136/ annrheumdis-2019-216852.

Smolen J, Genovese M, Takeuchi T, et al. THU0166 Safety profile of Baricitinib in patients with active RA: An integrated analysis. Ann Rheum Dis 2016;75:243-4.